Tiziana Life Sciences Ltd

NASDAQ•TLSA

CEO: Mr. Gabriele Marco Antonio Cerrone M.B.A.

セクター: Healthcare

業種: Biotechnology

上場日: 2018-11-20

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.

連絡先情報

14/15 Conduit Street, London, W1S 2XJ, United Kingdom

N/A

www.tizianalifesciences.com

時価総額

$65.37M

PER (TTM)

-4.1

24.5

配当利回り

52週高値

$2.60

52週安値

$1.04

52週レンジ

順位58Top 85.6%

2.3

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 2.3 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.22+0.00%

直近4四半期の推移

フリーCF

-$6.04M+0.00%

直近4四半期の推移

2024 FY 決算ハイライト

主なハイライト

Net Loss Significantly Reduced Net loss for the year $11.9M USD, representing a $5.7M improvement compared to the $17.7M loss in 2023.

Cash Burn Rate Decreased Cash used in operating activities $1.5M USD in 2024, a substantial decrease from $15.7M used during the 2023 period.

R&D Focus Shifted Total R&D expenses $5.2M USD in 2024, down $2.9M due to cessation of focus on the IL6-R asset.

SPMS Fast Track Status FDA granted Fast Track designation for intranasal Foralumab in non-active Secondary Progressive Multiple Sclerosis indication.

リスク要因

Need for Future Capital Requires substantial additional funding to complete development; failure risks delaying or terminating critical product development efforts.

Clinical Trial Uncertainty Substantial delays in clinical trials or failure to demonstrate safety/utility may prevent or delay required regulatory approvals.

Reliance on Third Parties Reliance on CROs/CMOs for trials and manufacturing; failure to perform could compromise data integrity and timelines.

IP License Compliance Risk Breach of existing license agreements or failure to secure new IP rights could impair competitive position and commercialization.

見通し

SPMS Phase 2a Data Phase 2a SPMS trial is ongoing; topline results are currently anticipated by the fourth quarter of 2025.

Alzheimer's Trial Initiation IND cleared for Alzheimer's Phase 1 trial; first patient dosed in December 2024 following FDA clearance.

ALS Trial Amendments Addressing FDA feedback on ALS trial design, including adding a placebo arm, to commence the 20-patient Phase 2a study.

Lean R&D Strategy Continue employing a lean, virtual R&D model to maximize value accretion by focusing resources on the lead asset.

同業比較

売上高 (TTM)

MGNX

$157.08M

+3.1%

IRD

$11.98M

-12.2%

SRZN

$7.49M

-35.6%

粗利益率 (最新四半期)

IRD

99.4%

-0.4pp

SRZN

98.7%

+0.0pp

MGNX

46.0%

+19.9pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
IRD	$328.84M	-32.8	6068.8%	38.8%
OVID	$303.33M	-7.0	-22.5%	0.6%
ARMP	$278.27M	-1.0	162.6%	535.4%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

25%

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年10月7日

EPS:-$0.08

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし